Director, HTA, Value & Evidence, Lung Cancer

Role Responsibilities: Lead development of the US evidence generation strategy for the lung cancer & precision medicine portfolio in Oncology. Coordinate inputs from US Medical, field-facing colleagues, US Market Access, cross-alliance partners, GASP and USMA to define evidence needs and integrate the strategy for launch and lifecycle. Design and execute HEOR studies (e.g., network meta-analyses; real-world evidence/non-interventional studies), including site engagement, chart abstraction, and retrospective data collection, from concept through publication. Develop US value & evidence strategy with US Medical and Global HV&E, including AMCP dossiers, systematic literature reviews, economic models, and tools to support reimbursement and access. Provide strategic input into clinical trial designs and PRO data analysis/interpretation to support reimbursement, differentiation negotiations, and patient access. Ensure appropriate dissemination of HEOR materials per regulatory guidance/internal SOPs (e.g., PVPs, promotional materials, FDAMA 114-compliant materials). Build external research collaborations with experts, healthcare policy makers, payers, and academic/community oncology settings. Qualifications: Graduate degree minimum (e.g., MSc/MPH/PhD) required. 7+ years with MSc/MPH/MBA; or 5+ years with PharmD/PhD in HEOR or related fields. Deep understanding of health services research methods (health economic modeling, PROs, statistics, real-world evidence/registries/observational design) and independent management of complex non-interventional studies. Knowledge of drug development and US healthcare/economic environment. Preferred Qualifications: Experience managing real-world evidence studies (sites, chart abstraction vendors, data quality oversight, protocol-aligned abstraction). Oncology/lung cancer experience. Experience with US healthcare environment and HTA submissions (e.g., ICER, CMS-IPAY/IRA, NICE). #J-18808-Ljbffr Scorpion Therapeutics